163 related articles for article (PubMed ID: 37927589)
1.
Mody H; Vaidya TR; Lezeau J; Taha K; Ait-Oudhia S
Front Pharmacol; 2023; 14():1239141. PubMed ID: 37927589
[TBL] [Abstract][Full Text] [Related]
2. In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization.
Mody H; Vaidya TR; Ait-Oudhia S
Sci Rep; 2023 Feb; 13(1):3100. PubMed ID: 36813809
[TBL] [Abstract][Full Text] [Related]
3. In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Fleisher B; Lezeau J; Werkman C; Jacobs B; Ait-Oudhia S
Breast Cancer (Dove Med Press); 2021; 13():87-105. PubMed ID: 33628047
[TBL] [Abstract][Full Text] [Related]
4. New Insights About Doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and Dexrazoxane Cytoprotective Effect: Contribution of
Dallons M; Schepkens C; Dupuis A; Tagliatti V; Colet JM
Front Pharmacol; 2020; 11():79. PubMed ID: 32153402
[TBL] [Abstract][Full Text] [Related]
5. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells.
Dallons M; Alpan E; Schepkens C; Tagliatti V; Colet JM
Cells; 2020 Sep; 9(10):. PubMed ID: 32992522
[TBL] [Abstract][Full Text] [Related]
6. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
[TBL] [Abstract][Full Text] [Related]
7. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
Imondi AR
Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
[TBL] [Abstract][Full Text] [Related]
8. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
9. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
10. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
[TBL] [Abstract][Full Text] [Related]
11. Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.
Calvé A; Haddad R; Barama SN; Meilleur M; Sebag IA; Chalifour LE
Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2048-57. PubMed ID: 22447943
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin.
Mody H; Vaidya TR; Lesko LJ; Ait-Oudhia S
Cells; 2022 Dec; 12(1):. PubMed ID: 36611850
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J
Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669
[TBL] [Abstract][Full Text] [Related]
14. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
[TBL] [Abstract][Full Text] [Related]
15. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells.
Sharma G; Tyagi AK; Singh RP; Chan DC; Agarwal R
Breast Cancer Res Treat; 2004 May; 85(1):1-12. PubMed ID: 15039593
[TBL] [Abstract][Full Text] [Related]
18. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
19. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
20. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
